Hemolytic anemia: a rare but potentially serious adverse effect of captopril.

Published

Journal Article

Captopril was the first oral angiotensin-converting enzyme (ACE) inhibitor available and, as such, has been extensively studied and in clinical use for many years. Several studies have defined captopril's efficacy in the treatment of congestive heart failure (CHF) as well as determined its safety profile. The most common adverse hematologic reactions associated with captopril use include neutropenia and agranulocytosis. This paper describes an uncommon and a potentially serious hematologic side effect associated with captopril-hemolytic anemia.

Full Text

Duke Authors

Cited Authors

  • Trimble, MA; Sketch, MH; Mehta, RH

Published Date

  • February 2007

Published In

Volume / Issue

  • 32 / 1

Start / End Page

  • 62 - 64

PubMed ID

  • 17323037

Pubmed Central ID

  • 17323037

Electronic International Standard Serial Number (EISSN)

  • 1615-6692

International Standard Serial Number (ISSN)

  • 0340-9937

Digital Object Identifier (DOI)

  • 10.1007/s00059-007-2956-5

Language

  • eng